BCBraden Corbin

Braden Corbin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Braden Corbin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Abbe R. Clark

    Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Anna Greka

    Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

    1 shared publication
  • Astrid Weins

    Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

    1 shared publication
  • Dan Brooks

    Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Eric Hesse

    Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    1 shared publication
  • Eugene P. Rhee

    Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication

Latest Publications

  • Open Access

    Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities

    by Marta Christov, Abbe R. Clark, Braden Corbin, Samy Hakroush, Eugene P. Rhee, Hiroaki Saito, Dan Brooks, Eric Hesse, Mary Bouxsein, Niels Galjart, et al.

    Progressive chronic kidney diseases (CKDs) are on the rise worldwide. However, the sequence of events resulting in CKD progression remain poorly understood. Animal models of CKD exploring these issues are confounded by systemic toxicities or surgical interventions to acutely induce kidney injury. Here we report the generation of a CKD mouse model through the inducible podocyte-specific ablation of an essential endogenous molecule, the chromatin structure regulator CCCTC-binding factor (CTCF), which leads to rapid podocyte loss (iCTCF pod–/– ). As a consequence, iCTCF pod–/– mice develop severe progressive albuminuria, hyperlipidemia, hypoalbuminemia, and impairment of renal function, and die within 8–10 weeks. CKD progression in iCTCF pod–/– mice leads to high serum phosphate and elevations in fibroblast growth factor 23 (FGF23) and parathyroid hormone that rapidly cause bone mineralization defects, increased bone resorption, and bone loss. Dissection of the timeline leading to glomerular pathology in this CKD model led to the surprising observation that podocyte ablation and the resulting glomerular filter destruction is sufficient to drive progressive CKD and osteodystrophy in the absence of interstitial fibrosis. This work introduces an animal model with significant advantages for the study of CKD progression, and it highlights the need for podocyte-protective strategies for future kidney therapeutics.